Federal Register Notice: FDA has determined the regulatory review period for Second Sight Medical Products’ Argus II Visual Stimulation System is 2,282 days for extending a patent which claims the medical device. The system is indicated for patients aged 25 years and older with bare or no light perception vision caused by advanced retinitis pigmentosa. To view this notice, click here.
